Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara ® (sarilumab) and Praluent ® (alirocumab) PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi ...

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...

Following the equity investment and strategic collaborations, a Sanofi representative will join Adagene ... the SAFEbody platform can be applied to a wide variety of antibody-based ...

Sanofi a nnounces €300 m illion collaboration with Blackstone Life Sciences to a dvance an i nnovative t reatment for m ultiple m yeloma. Investment will accelerate the overall Sarclisa ...

Terms of the CollaborationAs previously announced, under the terms of the collaboration agreement, for each of the three Sanofi designated immunology/inflammation targets, IGM will lead research ...

Within in the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think U.S. sales growth can rebound ...

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody formatSelection of IPH6101/SAR443 ...

PARIS, Nov 29 (Reuters) - French pharmaceutical company Sanofi-Aventis SA said on Thursday it was expanding its collaboration agreement with U.S. biotech partner Regeneron Pharmaceuticals Inc and ...

Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.